NASDAQ:LSTA Lisata Therapeutics (LSTA) Stock Price, News & Analysis $2.58 -0.01 (-0.39%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lisata Therapeutics Stock (NASDAQ:LSTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lisata Therapeutics alerts:Sign Up Key Stats Today's Range$2.51▼$2.5950-Day Range$2.39▼$2.9652-Week Range$1.87▼$4.20Volume12,748 shsAverage Volume31,617 shsMarket Capitalization$22.60 millionP/E RatioN/ADividend YieldN/APrice Target$23.50Consensus RatingBuy Company Overview Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Read More Lisata Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreLSTA MarketRank™: Lisata Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 432nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLisata Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Lisata Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lisata Therapeutics are expected to grow in the coming year, from ($2.66) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lisata Therapeutics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lisata Therapeutics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLisata Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lisata Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.70% of the float of Lisata Therapeutics has been sold short.Short Interest Ratio / Days to CoverLisata Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lisata Therapeutics has recently increased by 61.82%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLisata Therapeutics does not currently pay a dividend.Dividend GrowthLisata Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.70% of the float of Lisata Therapeutics has been sold short.Short Interest Ratio / Days to CoverLisata Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lisata Therapeutics has recently increased by 61.82%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.86 News SentimentLisata Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Lisata Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Lisata Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of Lisata Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.94% of the stock of Lisata Therapeutics is held by institutions.Read more about Lisata Therapeutics' insider trading history. Receive LSTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LSTA Stock News HeadlinesLSTA Q3 EPS Estimate Raised by Brookline Capital ManagementAugust 15, 2025 | americanbankingnews.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 25 at 2:00 AM | Brownstone Research (Ad)Lisata extends cash runway into Q4 2026 while advancing certepetide development milestonesAugust 9, 2025 | msn.comLisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comLisata Therapeutics advances lead cancer drug, expects key trial results by year-endAugust 7, 2025 | proactiveinvestors.comLisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comLisata Therapeutics Q2 2025 Earnings PreviewAugust 7, 2025 | msn.comSee More Headlines LSTA Stock Analysis - Frequently Asked Questions How have LSTA shares performed this year? Lisata Therapeutics' stock was trading at $2.98 at the beginning of the year. Since then, LSTA shares have decreased by 14.4% and is now trading at $2.55. How were Lisata Therapeutics' earnings last quarter? Lisata Therapeutics, Inc. (NASDAQ:LSTA) posted its earnings results on Thursday, August, 7th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.11. The firm earned $0.07 million during the quarter. Read the conference call transcript. Who are Lisata Therapeutics' major shareholders? Top institutional shareholders of Lisata Therapeutics include BML Capital Management LLC (2.40%) and Cerity Partners LLC (0.14%). How do I buy shares of Lisata Therapeutics? Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lisata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lisata Therapeutics investors own include PayPal (PYPL), JD.com (JD), NIO (NIO), Construction Partners (ROAD), Sunrun (RUN), ASE Technology (ASX) and Coinbase Global (COIN). Company Calendar Last Earnings8/07/2025Today8/25/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LSTA CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787Employees30Year FoundedN/APrice Target and Rating Average Price Target for Lisata Therapeutics$23.50 High Price Target$32.00 Low Price Target$15.00 Potential Upside/Downside+828.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.99 million Net MarginsN/A Pretax Margin-1,858.41% Return on Equity-69.68% Return on Assets-59.44% Debt Debt-to-Equity RatioN/A Current Ratio5.77 Quick Ratio5.77 Sales & Book Value Annual Sales$1 million Price / Sales22.16 Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.72Miscellaneous Outstanding Shares8,760,000Free Float7,959,000Market Cap$22.16 million OptionableNot Optionable Beta0.93 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:LSTA) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.